TOPICS / TUMOR TYPE

Liver cancer (HCC)

Hepatocellular carcinoma — a setting for neoantigen vaccines layered onto checkpoint-inhibitor backbones.

Topic2 items2026-05-30 – 2026-05-31

Tumor types

Melanoma10 Pancreatic cancer9 Glioblastoma9 Colorectal cancer7 Lung cancer (NSCLC)6 Lynch syndrome5 Kidney cancer (RCC)5 Breast cancer5 Head & neck cancer2 Liver cancer (HCC)2 Gastric cancer1 Bladder cancer1 Prostate cancer1

AI / Methods

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.

Analysis of the NASIR-HCC trial shows that neoantigen-specific immune responses can be detected in hepatocellular carcinoma patients, including those who did not benefit from radioimmunotherapy and nivolumab. In vivo experiments in HLA transgenic mice confirmed responses to predicted neoantigens, suggesting potential for vaccine-based strategies in non-responders.

europepmc · brief 2026-05-31 · published 2026-03-18

Clinical

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Geneos Therapeutics is conducting a Phase I/IIa single-arm study of GNOS-PV02, a personalized neoantigen DNA vaccine, combined with plasmid-encoded IL-12 (INO-9012) and pembrolizumab in advanced hepatocellular carcinoma (HCC). The trial is currently active but not recruiting, focusing on the combination of DNA-based immunization with immune checkpoint inhibition.

clinicaltrials · brief 2026-05-30 · published 2026-04-22